Related Experiment Videos
Antiplatelet therapy for elective coronary stenting: a moving target
1Division of Cardiology, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem, Belgium. mark.claeys@ua.ac.be
Seminars in Vascular Medicine
|June 17, 2004
Summary
Dual oral antiplatelet therapy, including aspirin and clopidogrel, significantly reduces ischemic complications after coronary stenting. Pretreatment is now preferred, potentially eliminating the need for glycoprotein IIb/IIIa antagonists in elective procedures.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Platelet-mediated mechanisms significantly contribute to thrombotic complications following coronary stenting.
- Dual oral antiplatelet therapy (aspirin and adenosine diphosphate antagonists) has been crucial in managing acute stent thrombosis.
Purpose of the Study:
- To evaluate the evolving role and optimal timing of dual oral antiplatelet therapy in coronary stenting.
- To assess the impact of pretreatment with dual oral antiplatelet therapy on ischemic complications.
Main Methods:
- Review of clinical data and treatment strategies for antiplatelet therapy post-coronary stenting.
- Analysis of the shift in timing and dosage of dual oral antiplatelet therapy, from post- to pre-intervention.
Main Results:
- Pretreatment with aspirin and clopidogrel demonstrated a 30% reduction in ischemic complications.
- Optimal pretreatment may render glycoprotein IIb/IIIa antagonists unnecessary for elective coronary stenting.
Conclusions:
- Pre-procedural dual oral antiplatelet therapy is a key strategy to minimize ischemic events after coronary stenting.
- Glycoprotein IIb/IIIa antagonists should be reserved for high-risk or acute coronary interventions when optimal pretreatment is achieved.